Aliases & Classifications for Anxiety Disorder

MalaCards integrated aliases for Anxiety Disorder:

Name: Anxiety Disorder 12 14
Anxiety 12 29 41 69
Anxiety Disorders 52 42 69
Anxiety State 12 69
Anxiety Neurosis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2030
ICD10 33 F41.9 F41.8
ICD9CM 35 300.09
MeSH 42 D001008
NCIt 47 C2878

Summaries for Anxiety Disorder

MedlinePlus : 41 fear and anxiety are part of life. you may feel anxious before you take a test or walk down a dark street. this kind of anxiety is useful - it can make you more alert or careful. it usually ends soon after you are out of the situation that caused it. but for millions of people in the united states, the anxiety does not go away, and gets worse over time. they may have chest pains or nightmares. they may even be afraid to leave home. these people have anxiety disorders. types include panic disorder obsessive-compulsive disorder post-traumatic stress disorder phobias generalized anxiety disorder treatment can involve medicines, therapy or both. nih: national institute of mental health

MalaCards based summary : Anxiety Disorder, also known as anxiety, is related to obsessive-compulsive personality disorder and dyspepsia, and has symptoms including nervousness, agitation and feeling tense. An important gene associated with Anxiety Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and testes, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 72 Anxiety disorders are a group of mental disorders characterized by significant feelings of anxiety and... more...

Related Diseases for Anxiety Disorder

Diseases related to Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
id Related Disease Score Top Affiliating Genes
1 obsessive-compulsive personality disorder 29.5 BDNF COMT HTR1A HTR2A MAOA SLC6A4
2 dyspepsia 29.4 CCK NPY
3 pervasive developmental disorder 28.9 BDNF CCK COMT OXT SLC6A2 SLC6A3
4 schizophrenia 27.9 BDNF CCK COMT CYP2D6 DRD2 HTR1A
5 personality disorder 26.9 BDNF CCK COMT CRH CYP2D6 DRD2
6 generalized anxiety disorder 12.5
7 separation anxiety disorder 12.3
8 panic disorder 11.6
9 agoraphobia 11.2
10 phobia, specific 11.2
11 obsessive-compulsive disorder 11.1
12 bipolar disorder 11.0
13 phobic disorder 11.0
14 post-traumatic stress disorder 10.9
15 eating disorder 10.9
16 neurotic disorder 10.9
17 social phobia 10.8
18 neurogenic bladder 10.7 HTR2A MAOA SLC6A4
19 paranoid personality disorder 10.7 HTR1A HTR2A
20 conjunctival degeneration 10.7 HTR1A HTR2A SLC6A4
21 hyperthyroxinemia 10.7 DRD2 HTR2A SLC6A4
22 polyneuropathy 10.7 HTR1A HTR2A
23 intracranial cavernous angioma 10.7 DRD2 SLC6A3 SLC6A4
24 ulcerative colitis 10.6 BDNF COMT DRD2
25 allergic hypersensitivity disease 10.6 DRD2 HTR1A HTR2A
26 eosinophilia-myalgia syndrome 10.6 BDNF DRD2 SLC6A3
27 luxation of globe 10.6 HTR1A NPY SLC6A4
28 vascular cancer 10.6 DRD2 HTR1A HTR2A
29 brain meningioma 10.6 BDNF COMT DRD2
30 hodgkin's granuloma 10.6 HTR1A HTR2A
31 uterus intravascular leiomyomatosis 10.6 COMT HTR1A MAOA SLC6A4
32 ring chromosome 14 syndrome 10.6 COMT MAOA
33 intellectual developmental disorder with gastrointestinal difficulties and high pain threshold 10.6
34 elective mutism 10.6
35 acute stress disorder 10.6
36 aids - neurological complications 10.6
37 alcoholic liver cirrhosis 10.6 BDNF DRD2 SLC6A4
38 acute female pelvic peritonitis 10.6 DRD2 SLC6A3 SLC6A4
39 anosognosia 10.6 COMT DRD2 HTR1A SLC6A4
40 pompholyx 10.5 DRD2 HTR1A HTR2A SLC6A4
41 myopathy, distal, with early respiratory failure, autosomal dominant 10.5 COMT SLC6A3 TPH1
42 splenic abscess 10.5 DRD2 HTR2A SLC6A3 SLC6A4
43 suppurative periapical periodontitis 10.5 DRD2 SLC6A4 TPH1
44 abnormal pupillary function 10.5 HTR1A HTR3A
45 rhinoscleroma 10.5 COMT DRD2
46 angiokeratoma of mibelli 10.5 HTR1A MAOA SLC6A2 SLC6A4
47 contact dermatitis 10.5 DRD2 HTR2A SLC6A3 TPH2
48 chitty hall webb syndrome 10.4 COMT TPH1
49 chorea gravidarum 10.4 CYP2D6 DRD2 HTR1A
50 anodontia 10.4 HTR1A HTR3A SLC6A3 SLC6A4

Comorbidity relations with Anxiety Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 79)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Benign Paroxysmal Positional Nystagmus
Borderline Personality Disorder Bronchiectasis
Bronchitis Bronchopneumonia
Cerebrovascular Disease Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Chronic Rhinitis
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Malignant Essential Hypertension Meniere's Disease
Migraine with or Without Aura 1 Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder

Graphical network of the top 20 diseases related to Anxiety Disorder:



Diseases related to Anxiety Disorder

Symptoms & Phenotypes for Anxiety Disorder

UMLS symptoms related to Anxiety Disorder:


nervousness, agitation, feeling tense, mental and behavioral signs and symptoms, feeling jittery, sleeplessness

GenomeRNAi Phenotypes related to Anxiety Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A SLC6A4 HTR1A
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Anxiety Disorder:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 BDNF CCK COMT CRH CRHR1 DRD2
2 homeostasis/metabolism MP:0005376 10.39 OXT SLC6A2 SLC6A3 SLC6A4 TPH1 TPH2
3 growth/size/body region MP:0005378 10.27 SLC6A2 SLC6A3 SLC6A4 TPH1 TPH2 TSPO
4 nervous system MP:0003631 10.27 ADCYAP1R1 BDNF CCK COMT CRH CRHR1
5 endocrine/exocrine gland MP:0005379 10.26 BDNF CCK COMT CRH CRHR1 DRD2
6 cardiovascular system MP:0005385 10.24 COMT CRHR1 DRD2 HTR1A MAOA OXT
7 integument MP:0010771 10.1 BDNF CRH DRD2 HTR3A OXT SLC6A2
8 adipose tissue MP:0005375 10 CRH DRD2 NPY OXT TPH1 TPH2
9 normal MP:0002873 9.96 ADCYAP1R1 BDNF CRH CRHR1 DRD2 NPY
10 no phenotypic analysis MP:0003012 9.92 CRH CRHR1 DRD2 HTR1A TPH2 ADCYAP1R1
11 renal/urinary system MP:0005367 9.63 COMT CRH DRD2 HTR3A NPY OXT
12 respiratory system MP:0005388 9.5 CRH CRHR1 DRD2 TPH1 TPH2 BDNF
13 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Anxiety Disorder

Drugs for Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1310)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 99-66-1 3121
3
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148553-50-8 5486971
4
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10024-97-2 948
5
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 36505-84-7 2477
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
7
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
8
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
9
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1 154598-52-4 64139
10
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
11
Rilpivirine Approved Phase 4 500287-72-9
12
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
13
Moxonidine Approved Phase 4 75438-57-2 4810
14
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
15
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2078-54-8 4943
16
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 439-14-5 3016
17
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
18
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
19
Etomidate Approved Phase 4,Phase 2 33125-97-2 36339 667484
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
22
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
23
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
24
Drospirenone Approved Phase 4,Phase 1 67392-87-4 68873
25
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
26
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
27
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
28
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
29
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
30
Nitric Oxide Approved Phase 4,Phase 1,Phase 2 10102-43-9 145068
31
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 27203-92-5 33741
32
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
33
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 1 54739-18-3 3404 5324346
34
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
35
Mianserin Approved Phase 4,Phase 3,Phase 2 24219-97-4 4184
36
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-52-8, 61337-67-5 4205
37
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
38
Topiramate Approved Phase 4,Phase 3,Phase 2 97240-79-4 5284627
39
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
40
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
41
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
42
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
43
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 298-46-4 2554
44
Coal tar Approved Phase 4,Phase 1 8007-45-2
45
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
46
Oxcarbazepine Approved Phase 4,Phase 3 28721-07-5 34312
47
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
48
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
49
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
50
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073

Interventional clinical trials:

(show top 50) (show all 8809)

id Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
4 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
5 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
6 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
7 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
8 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
9 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
10 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
11 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
12 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
13 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
14 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
15 Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Unknown status NCT02042001 Phase 4 Immediate switch to TDF/FTC/RPV;Switch to TDF/FTC/RPV after 12 weeks
16 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
17 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
18 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
19 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
20 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
21 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
22 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
23 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
24 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
25 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
26 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
27 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
28 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
29 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
30 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
31 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
32 MEOPA Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling. Unknown status NCT02573987 Phase 4 Equimolar Mix of Oxygen and Nitrogen Monoxide;Lidocaïn
33 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
34 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
35 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
36 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
37 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
38 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
39 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4
40 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
41 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
42 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
43 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
44 Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder Unknown status NCT00134446 Phase 4
45 Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain Unknown status NCT02125968 Phase 4
46 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
47 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
48 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
49 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
50 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy

Search NIH Clinical Center for Anxiety Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety Disorder

Genetic tests related to Anxiety Disorder:

id Genetic test Affiliating Genes
1 Anxiety 29

Anatomical Context for Anxiety Disorder

MalaCards organs/tissues related to Anxiety Disorder:

39
Breast, Brain, Testes, Heart, Prostate, Lung, Spinal Cord

Publications for Anxiety Disorder

Articles related to Anxiety Disorder:

(show top 50) (show all 1400)
id Title Authors Year
1
Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. ( 28886500 )
2018
2
Failure in Cognitive Suppression of Negative Affect in Adolescents with Generalized Anxiety Disorder. ( 28747683 )
2017
3
Brain structural changes in late-life generalized anxiety disorder. ( 28837828 )
2017
4
Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. ( 28771530 )
2017
5
Modification of the medical exclusion criterion in DSM-5 social anxiety disorder: Comorbid obesity as an example. ( 28064111 )
2017
6
Using interpersonal process recall to compare patients' accounts of resistance in two psychotherapies for generalized anxiety disorder. ( 28910493 )
2017
7
Integrating iCBT for generalized anxiety disorder into routine clinical care: Treatment effects across the adult lifespan. ( 28926805 )
2017
8
The relationship of social anxiety disorder symptoms with probable attention deficit hyperactivity disorder in Turkish university students; impact of negative affect and personality traits of neuroticism and extraversion. ( 28460287 )
2017
9
Affective neuroimaging in generalized anxiety disorder: an integrated review. ( 28867941 )
2017
10
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. ( 28075650 )
2017
11
Resting state functional connectivity in primary insomnia, generalized anxiety disorder and controls. ( 28500965 )
2017
12
Serotonin-Related Gene Variants in Patients with Irritable Bowel Syndrome and Depressive or Anxiety Disorders. ( 28951738 )
2017
13
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28947609 )
2017
14
Predicting cognitive behavioral therapy response in social anxiety disorder with anterior cingulate cortex and amygdala during emotion regulation. ( 28462086 )
2017
15
Resting-state functional connectivity in generalized anxiety disorder and social anxiety disorder: Evidence for a dimensional approach. ( 28478685 )
2017
16
Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. ( 28529365 )
2017
17
Genetics of generalized anxiety disorder and related traits. ( 28867940 )
2017
18
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
19
Combining Metacognitive Strategies with Traditional Cognitive Behavior Therapy in Generalized Anxiety Disorder: A Case Illustration. ( 28515551 )
2017
20
The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. ( 28766128 )
2017
21
The Center for Epidemiologic Studies Depression Scale is an adequate screening instrument for depression and anxiety disorder in adults with congential heart disease. ( 28874154 )
2017
22
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
23
Generalized Anxiety Disorder, worry and attention to threat: A systematic review. ( 28448826 )
2017
24
Does internet-based cognitive behaviour therapy reduce healthcare costs and resource use in treatment of social anxiety disorder? A cost-minimisation analysis conducted alongside a randomised controlled trial. ( 28899892 )
2017
25
Feeling safe but appearing anxious: Differential effects of alcohol on anxiety and social performance in individuals with social anxiety disorder. ( 28441522 )
2017
26
The history of generalized anxiety disorder as a diagnostic category. ( 28867935 )
2017
27
On the context dependency of implicit self-esteem in social anxiety disorder. ( 28511035 )
2017
28
Biological markers of generalized anxiety disorder. ( 28867939 )
2017
29
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
30
Spontaneous alterations of regional brain activity in patients with adult generalized anxiety disorder. ( 28790831 )
2017
31
Family accommodation of anxiety symptoms in youth undergoing intensive multimodal treatment for anxiety disorders and obsessive-compulsive disorder: Nature, clinical correlates, and treatment response. ( 28892781 )
2017
32
Collaborative care for panic disorder, generalised anxiety disorder and social phobia in general practice: study protocol for three cluster-randomised, superiority trials. ( 28814317 )
2017
33
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
34
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
35
Childhood adversity, adult stress, and the risk of major depression or generalized anxiety disorder in US soldiers: a test of the stress sensitization hypothesis. ( 28443533 )
2017
36
Bidirectional association between Bell's palsy and anxiety disorders: A nationwide population-based retrospective cohort study. ( 28359982 )
2017
37
Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders. ( 27346075 )
2017
38
Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis. ( 28477500 )
2017
39
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
40
The association of generalized anxiety disorder and Somatic Symptoms with frequent attendance to health care services: A cross-sectional study from the Northern Finland Birth Cohort 1966. ( 28792287 )
2017
41
Error-Specific Cognitive Control Alterations in Generalized Anxiety Disorder. ( 28871288 )
2017
42
Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. ( 28903922 )
2017
43
A case of paroxysmal kinesigenic dyskinesia which exhibited the phenotype of anxiety disorder. ( 28860775 )
2017
44
The influence of attention biases and adult attachment style on treatment outcome for adults with social anxiety disorder. ( 28441619 )
2017
45
Testing the metacognitive model against the benchmark CBT model of social anxiety disorder: Is it time to move beyond cognition? ( 28472176 )
2017
46
Adult separation anxiety disorder in complicated grief: an exploratory study on frequency and correlates. ( 27683967 )
2017
47
Environmental transmission of generalized anxiety disorder from parents to children: worries, experiential avoidance, and intolerance of uncertainty. ( 28867938 )
2017
48
Prevalence of generalized anxiety disorder and major depression in health-care givers of disabled patients in Majmaah and Shaqra cities, Kingdom of Saudi Arabia. ( 28936144 )
2017
49
Pathways from uncertainty to anxiety: An evaluation of a hierarchical model of trait and disorder-specific intolerance of uncertainty on anxiety disorder symptoms. ( 27984787 )
2017
50
Client Retrospective Accounts of Corrective Experiences in Motivational Interviewing Integrated With Cognitive Behavioral Therapy for Generalized Anxiety Disorder. ( 28072459 )
2017

Variations for Anxiety Disorder

Copy number variations for Anxiety Disorder from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139649 2 185171337 185512459 Deletion ZNF804A anxiety disorder

Expression for Anxiety Disorder

Search GEO for disease gene expression data for Anxiety Disorder.

Pathways for Anxiety Disorder

Pathways related to Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 ADCYAP1R1 CCK CRH CRHR1 DRD2 HTR1A
2
Show member pathways
12.59 ADCYAP1R1 COMT DRD2 MAOA SLC6A3
3 12.4 COMT HTR1A NPY TPH1 TPH2
5
Show member pathways
12.07 ADCYAP1R1 BDNF DRD2 HTR1A NPY
6
Show member pathways
11.85 BDNF DRD2 MAOA SLC6A3
7 11.82 ADCYAP1R1 BDNF HTR1A HTR2A HTR3A MAOA
8 11.81 CYP2D6 HTR1A HTR2A HTR3A MAOA SLC6A4
9
Show member pathways
11.79 DRD2 HTR1A HTR2A
10
Show member pathways
11.29 MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
11
Show member pathways
11.05 COMT MAOA SLC6A3 SLC6A4
12
Show member pathways
10.98 COMT MAOA TPH1
13 10.69 COMT MAOA
14
Show member pathways
10.68 COMT MAOA
15 10.61 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
16 10.36 CRH CRHR1

GO Terms for Anxiety Disorder

Cellular components related to Anxiety Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 ADCYAP1R1 CRHR1 DRD2 HTR1A HTR2A SLC6A2
2 neuronal cell body GO:0043025 9.65 CCK CRH HTR2A HTR3A SLC6A3
3 perikaryon GO:0043204 9.5 CCK CRH DRD2
4 neuron projection GO:0043005 9.43 ADCYAP1R1 SLC6A2 SLC6A3 SLC6A4 TPH1 TPH2
5 axon GO:0030424 9.1 CCK COMT DRD2 HTR2A HTR3A SLC6A3
6 integral component of membrane GO:0016021 10.18 ADCYAP1R1 COMT CRHR1 CYP2D6 DRD2 HTR1A

Biological processes related to Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.95 CRH HTR2A NPY SLC6A2
2 steroid metabolic process GO:0008202 9.87 CRH CYP2D6 TSPO
3 response to estradiol GO:0032355 9.86 ADCYAP1R1 OXT SLC6A4
4 circadian rhythm GO:0007623 9.83 SLC6A4 TPH1 TPH2
5 memory GO:0007613 9.78 HTR2A OXT SLC6A4
6 response to ethanol GO:0045471 9.77 ADCYAP1R1 CRH DRD2 HTR3A SLC6A3
7 female pregnancy GO:0007565 9.76 COMT CRH CRHR1 OXT
8 neurotransmitter transport GO:0006836 9.74 SLC6A2 SLC6A3 SLC6A4
9 negative regulation of blood pressure GO:0045776 9.7 CRH DRD2 OXT
10 synaptic transmission, dopaminergic GO:0001963 9.69 CRH DRD2
11 vasoconstriction GO:0042310 9.69 HTR1A SLC6A4
12 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.68 DRD2 HTR2A
13 dopamine metabolic process GO:0042417 9.68 COMT DRD2
14 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
15 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 CRHR1 DRD2
16 grooming behavior GO:0007625 9.67 DRD2 OXT
17 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
18 regulation of sensory perception of pain GO:0051930 9.67 CCK COMT OXT
19 prepulse inhibition GO:0060134 9.66 DRD2 SLC6A3
20 positive regulation of renal sodium excretion GO:0035815 9.66 DRD2 OXT
21 sleep GO:0030431 9.65 HTR2A OXT
22 neurotransmitter catabolic process GO:0042135 9.64 COMT MAOA
23 catecholamine metabolic process GO:0006584 9.64 COMT MAOA
24 positive regulation of mitochondrial depolarization GO:0051901 9.63 CCK TSPO
25 parturition GO:0007567 9.63 CRH CRHR1
26 regulation of dopamine metabolic process GO:0042053 9.62 HTR1A SLC6A3
27 adenohypophysis development GO:0021984 9.62 DRD2 SLC6A3
28 regulation of behavior GO:0050795 9.61 HTR1A HTR2A
29 behavior GO:0007610 9.61 HTR1A HTR2A NPY
30 aromatic amino acid family metabolic process GO:0009072 9.6 TPH1 TPH2
31 sperm ejaculation GO:0042713 9.59 OXT SLC6A4
32 regulation of hormone secretion GO:0046883 9.58 HTR1A HTR2A
33 indolalkylamine biosynthetic process GO:0046219 9.58 TPH1 TPH2
34 monoamine transport GO:0015844 9.58 SLC6A2 SLC6A3 SLC6A4
35 serotonin receptor signaling pathway GO:0007210 9.56 HTR1A HTR2A
36 response to ether GO:0045472 9.55 CRH OXT
37 serotonin biosynthetic process GO:0042427 9.54 TPH1 TPH2
38 dopamine catabolic process GO:0042420 9.5 COMT MAOA SLC6A3
39 regulation of serotonin secretion GO:0014062 9.48 CRH HTR1A
40 response to pain GO:0048265 9.46 COMT CRH SLC6A2 TSPO
41 dopamine uptake involved in synaptic transmission GO:0051583 9.43 SLC6A2 SLC6A3 SLC6A4
42 response to cocaine GO:0042220 9.35 CRH DRD2 HTR3A OXT SLC6A3
43 response to drug GO:0042493 9.28 ADCYAP1R1 COMT CRH DRD2 HTR2A SLC6A2
44 signal transduction GO:0007165 10.16 ADCYAP1R1 CCK CRH CRHR1 DRD2 HTR1A

Molecular functions related to Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.93 ADCYAP1R1 CRHR1 DRD2 HTR1A HTR2A NPY
2 hormone activity GO:0005179 9.71 CCK CRH NPY OXT
3 symporter activity GO:0015293 9.69 SLC6A2 SLC6A3 SLC6A4
4 drug binding GO:0008144 9.62 CYP2D6 DRD2 HTR2A SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.49 SLC6A3 SLC6A4
6 dopamine binding GO:0035240 9.48 DRD2 SLC6A3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.43 TPH1 TPH2
8 serotonin binding GO:0051378 9.43 HTR1A HTR2A HTR3A
9 tryptophan 5-monooxygenase activity GO:0004510 9.37 TPH1 TPH2
10 monoamine transmembrane transporter activity GO:0008504 9.33 SLC6A2 SLC6A3 SLC6A4
11 neuropeptide hormone activity GO:0005184 9.26 CCK CRH NPY OXT
12 dopamine:sodium symporter activity GO:0005330 8.8 SLC6A2 SLC6A3 SLC6A4

Sources for Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....